# Positron Emission Tomography (PET) Study to Describe the Relationship Between Plasma Concentrations and Brain Gly-T1 Occupancy of GSK1018921 Over Time.

> **NCT00945503** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 12 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** GSK1018921

## Key facts

- **NCT ID:** NCT00945503
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05-19
- **Primary completion:** 2008-12-22
- **Final completion:** 2008-12-22
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00945503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00945503, "Positron Emission Tomography (PET) Study to Describe the Relationship Between Plasma Concentrations and Brain Gly-T1 Occupancy of GSK1018921 Over Time.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00945503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*